Stock Trade Compilation Episode Nueve

94 Views07 Jul 2026 14:24

Syndicated

SUMMARY

Uncy is a drug company targeting renal patients.
The company got its second Complete Response Letter on June 30 and fell 40% to $5.
The FDA raised no efficacy or safety concerns, asked for no new data, and rejected the thing over the same third-party manufacturing deficiencies as the June 2025 CRL.

Try Now

Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:

Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.

Upgrade later to our paid plans for full-access.

SMARTKARMA PREVIEW PASS

By signing up, you agree to our
Terms of Use and Privacy Policy.

Already have an account? Sign In Now

Discussions

(Paid Plans Only)

Insight Stream